Longeveron (NASDAQ:LGVN – Get Free Report) and IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Earnings and Valuation
This table compares Longeveron and IDEAYA Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longeveron | $1.20 million | 4.23 | -$22.70 million | ($9.90) | -0.16 |
| IDEAYA Biosciences | $218.71 million | 14.51 | -$113.70 million | ($1.94) | -18.62 |
Longeveron has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Longeveron and IDEAYA Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
| IDEAYA Biosciences | -75.93% | -16.73% | -15.34% |
Volatility and Risk
Longeveron has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Longeveron and IDEAYA Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
| IDEAYA Biosciences | 1 | 1 | 14 | 0 | 2.81 |
Longeveron presently has a consensus price target of $80.00, indicating a potential upside of 4,931.45%. IDEAYA Biosciences has a consensus price target of $53.42, indicating a potential upside of 47.89%. Given Longeveron’s higher probable upside, analysts clearly believe Longeveron is more favorable than IDEAYA Biosciences.
Institutional and Insider Ownership
10.0% of Longeveron shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
IDEAYA Biosciences beats Longeveron on 10 of the 14 factors compared between the two stocks.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
